he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
详细信息信源地址
上一页:哪些抗菌药物可抑制癫痫?
下一页:全面性中风的先兆研究
- 2022-04-25全面性中风的先兆研究
- 2022-04-252013年国际抗癫痫理事会抗癫痫药使用指南
- 2022-04-20青少年癫痫病都有哪些病症导致的
- 癫痫患者手术评估新型工具
- FDA批准Aptiom用于治疗患者癫痫发作
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 预测癫痫患者再入院风险
- 癫痫定位新方法:无框架立体定向脑电图技术
- 心理百科:春节期间小心疾病
- 癫痫治疗障碍仍难以克服
- NeuroImage:纤维球成像可用于癫痫的进展
- 2015第31届国际癫痫大会(IEC)
- UCB的Vimpat癫痫新适应症在美国获批
- 羊角病能生孩子吗?
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 2016AAN:神经专家发表了有前途的专业见解
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 癫痫会遗传吗 癫痫的治疗方法
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫吃什么食物好?
- 不注意这些问题,吃多少药都没用!
- 成人羊角风病的病因是什么?
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 综述:癫痫持续状态诊治最新进展
- 癫痫发作的症状是什么?
- 2013国际抗癫痫联合会抗癫痫药用指南
- 月经性癫痫患者妊娠期癫痫控制更好
- 外科手术隐源性癫痫病要多少钱
- 睡眠不好怎么办 睡眠不好居然会致命(2)
- 怎样化疗癫痫癫痫病能化疗好吗
- 癫痫疾病要怎么治疗 癫痫病的类固醇选择
- 癫痫病肉什么可以控制
- 小儿癫痫的发作症状有哪些
- 羊角风患可以生孩子吗
- 焦虑百科:解读“幼稚病”
- 有利于癫痫病治疗的日常习惯上
- 猪血的做法 老少皆宜的补血豆制品(14)
- 治疗癫痫病近来哪些好啊
- 癫痫病应该怎样病患 癫痫病病患要多少钱
- 怎样治疗癫痫病最必要